IVL-Facilitated Transfemoral TAVR
Study Now Published
MINIMIZE TRAUMA – Minimize trauma to soft tissue by safely selecting and fracturing intimal and medial calcium
OPTIMIZE OUTCOMES – Optimize outcomes while reducing complications and cost escalation
SIMPLIFY PROCEDURES – Simple and intuitive system that makes complex calcified procedures more predictable
The First Applications of
Learn more about the potential of IVL in patients with aortic stenosis (AS) or IVL as a means to facilitate transfemoral access and avoid alternative routes by clicking on one of the below:
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
The results of #DISRUPTPAD3, the largest level 1 evidence in calcified #PAD, show that #ShockwaveIVL is a superior… https://t.co/OpI5W5bxgc
Gain insight on #IntravascularLithotripsy in calcified coronary lesions from Dr. @SBasavarajaiah & Dr. Alfonso Iela… https://t.co/21J8DZHJTj
There’s good prep, and then there’s superior prep. Hear the difference - the results of #DISRUPTPAD3 - from Dr. Bil… https://t.co/lZB1Q9OsL0
EU physicians, hear a thoughtful discussion on the significance of #DISRUPTCAD3, the largest & most rigorous corona… https://t.co/klTg7a92HC
New Year, New Reimbursement for Peripheral #ShockwaveIVL! CMS has introduced new coding & added sites of service fo… https://t.co/Y8kkidN4n8
Is imaging necessary or a nice-to-have for coronary #ShockwaveIVL cases? Hear from calcium experts Drs. @DrJMHill,… https://t.co/mGqf6XcMHm
See what Superiority looks like! Explore the #DISRUPTPAD3 infographic on #TheCatalystBlog to learn about… https://t.co/2NFQx3EOBJ
We love to hear it! Thank you Dr. @a_saratzis for sharing your outstanding result with #ShockwaveIVL & #DCB, and op… https://t.co/05FCkaIHBR
Don’t miss the #ShockwaveIVL Reimbursement Updates for 2021! CMS has introduced new coding & added sites of service… https://t.co/uo03Jv6N0a
EU interventionalists, see the #DISRUPTCAD3 results in new ways! Watch an animated infographic of the key findings,… https://t.co/5VoLDYvAMW
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
